Despite the legal setback for President Trump’s country-specific tariffs, he retains the authority to impose Section 232 tariffs on pharmaceuticals imported to the U.S.
The CDMO’s “conservative” guidance is due to limited visibility around a pending customer confirmation for a large contract that could impact sales growth this year.
The CRDMO’s hiring spree aims to meet rising global demand and support expanded active pharmaceutical ingredient capacity across its India and international sites.
